INTRODUCTION
Newborn screening (NBS) for cystic fibrosis has been a struggle to introduce in many parts of the world, with Health Service managers demanding proof that it was cost-effective. The evidence-base consisted of one randomized controlled trial (Wisconsin [1] ) and observational studies, largely comparing outcomes before and after the start of screening or between different geographical areas that did and did not deploy NBS (both have obvious confounders). The battle over NBS has been won, with universal acknowledgement of benefit. It must be acknowledged that NBS programs are not designed to detect 100% of newborns with cystic fibrosis, with most accepting a 5-10% false-negative rate.
Understanding the factors responsible for initiation and progression of lung disease in early life is of the utmost importance. Most current treatment in infancy and the preschool years is based on 'expert' opinion and not randomized controlled trials [2, 3] , and if trials are to be performed with lung function as an end-point, then the natural history of lung function must be known in order to adequately power studies. Also, if lung function deteriorates early, then novel molecular therapies such as ivacaftor and lumacaftor should be deployed early; whereas if conventional therapies maintain lung health for some years, these can wait until the child has passed the very vulnerable window of early lung development. With the increasing longevity of cystic fibrosis patients, and therefore the likelihood that treatment will be extended over decades with the risk of subtle cumulative toxicities, the longer treatments with unknown long-term safety profiles can safely be deferred, the better; however, if delay means irreversible damage is not prevented, this is not a good strategy.
The present article will briefly review early studies, but mainly focus on the two large prospective cohorts of babies, Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF) (Australia) and the London CF Collaborative (UK) studies, which have produced seemingly different results, in order to try to answer these two key points. Lung function, when possible, will be related to lung structure, infection and inflammation, but nutritional and other outcomes, although important, will not be discussed in detail.
WHAT DID WE LEARN FROM WISCONSIN?
In this unique study conducted between 1985 and 1991, 650 341 newborns underwent bloodspot testing for immunoreactive trypsin (iRT), followed by testing for DF 508 mutation analysis if iRT was positive. Only infants whose bloodspot number ended in an odd digit were recalled for sweat testing if cystic fibrosis was suspected; the others were diagnosed only when symptoms developed. Seventy-four of the 325 171 infants were diagnosed with cystic fibrosis in the screening group, including five in whom NBS missed the diagnosis. There were 40 cystic fibrosis diagnoses in the symptomatic group. At 10-year follow-up, nutrition was significantly better in the NBS diagnosis group, but by contrast, lung function was the same and chest radiograph abnormalities were worse in the NBS group, which also had more Pseudomonas aeruginosa acquisition [4] . This finding may relate to cystic fibrosis centre care at the time falling short of modern standards of prevention of cross-infection, but raised concerns about whether cystic fibrosis NBS and early institution of specialist treatment could prevent lung disease.
THE EARLY DAYS: CYSTIC FIBROSIS NEWBORN SCREENING IS ASSOCIATED WITH IMPROVED LUNG FUNCTION AND STRUCTURE
Unlike the Wisconsin study, the early studies were associative and confounded; they are discussed in a good review [5] , and briefly summarized here. Most [6] [7] [8] [9] [10] , but not all [11] , physiological studies have shown significant benefit from cystic fibrosis NBS diagnosis extending over many years. Imaging studies have shown that NBS-diagnosed babies had less structural lung disease at diagnosis than symptomatic diagnoses [10] [11] [12] [13] . These improvements are despite a lesser intensity [13] and lower cost of treatments [14] . Overall, it is clear that pulmonary function and respiratory outcomes are better in the medium to long term after diagnosis by NBS in these studies.
WHAT ARE WE LEARNING FROM PROSPECTIVE COHORT STUDIES?
There are two large prospective cohorts; here we discuss the similarities and differences between them. These are summarized in Table 1 .
LCFC studies
The first cohort, recruited between 1999 and 2002, was diagnosed in the first 2 years of life because of symptoms, and was compared with contemporaneous controls; both groups are now being re-studied in adolescence. The findings are reported here to contrast with the NBS studies. At diagnosis, in the first 2 years of life, there was evidence of airflow obstruction even in those babies who had never had respiratory symptoms [15] . This is not surprising, given the numerous bronchoscopic studies which have revealed evidence of infection and inflammation, even in apparently symptom-free cystic fibrosis babies [16] [17] [18] [19] [20] . Despite specialist treatment, there was no catch-up growth, either over the next 6 months [21] -a finding reported by others [22] -or into school-age [23] . During the time period of this cohort study, there were significant developments in clinical physiology which informed NBS studies.
KEY POINTS
Prognosis for lung health has improved dramatically with the advent of cystic fibrosis NBS.
Despite NBS diagnosis and institution of early treatment, lung function is impaired at 3 months of age.
Although the data are controversial, it is likely that lung function and high resolution computed tomographic (HRCT) in the first 2 years of life are too well preserved to allow them to be used as clinical trial end-points.
Bronchoscopy and HRCT cannot be recommended as routine cystic fibrosis (CF) clinical care, outside the context of clinical trials.
Although prognosis is improving, we need better pointof-care biomarkers to drive the early treatment of cystic fibrosis infants diagnosed on NBS.
Firstly, use of the raised-volume, thoraco-abdominal compression technique (RVRTC) was shown to be more sensitive than partial forced expiratory manoeuvres [24] . It became appreciated that many preschool children could perform spirometry, and quality control criteria were set for this procedure [25] . Finally, and most significantly, multiple breath washout was revived as a technique requiring only passive cooperation, and lung clearance index (LCI) was introduced into longitudinal follow-up.
Since LCI has become increasingly significant in cystic fibrosis research, it is important to be aware of what it can and cannot deliver. The test is based on the conventional nitrogen washout, but has been revived using an inert marker gas -sulphur hexafluoride (SF 6 ) mixed with air. The child inhales the gas mixture with normal tidal breathing until a wash-in equilibrium has been reached. The inspiratory gas flow is detached during expiration, and thereafter, SF 6 is washed out with air, again during normal tidal breathing. LCI is calculated as the number of lung turnovers required to reduce exhaled (SF 6 ) to one-fortieth of the initial concentration -a value of no physiological significance, but set by the sensitivity of early gas analysers. From the age of about 6 years to middle age, the upper limit of normal of LCI is the same, irrespective of height and weight. In early life, LCI is higher [26] and there is some evidence of elevation in older patients [27] ; however, confirmation in other cohorts would be valuable. There are international guidelines regarding standards of measurement [28] . Recently, because SF 6 is a greenhouse gas not registered for human use in most countries, LCI is being increasingly calculated using conventional nitrogen washout. What is important to state is that SF 6 and nitrogen washouts do not give comparable results, nor can results from different types of commercial equipment be compared [29 & ]. Furthermore, 100% O 2 may not be suitable for use in infants and young children as it may alter the breathing pattern [30 & ]. Recently, it has proved possible to shorten the LCI manoeuvre to make it more acceptable for young children [31] [32] [33] [34] .
LCI was shown to be more sensitive than spirometry or plethysmography in older children [35, 36] and in prospective studies to become abnormal before other lung function markers [36, 37] . However, both LCI and RVRTC missed infants with abnormal lung function, so both had to be performed [38] . An abnormal LCI at age 4 years was shown to be predictive of subsequent abnormal lung function [39] . London Cystic Fibrosis Collaboration (LCFC) and others [40, 41] showed that LCI was very sensitive to HRCT abnormalities in older children. Finally, elevation in LCI has been shown to be predictive of cystic fibrosis pulmonary exacerbations [42 & ] (or better, cystic fibrosis lung attacks [43, 44] ) and responsive to intravenous antibiotics [45] , and is a sensitive end-point in clinical trials [46] [47] [48] [49] . In trials involving cystic fibrosis patients with only mild spirometric abnormalities, LCI is a more sensitive marker of response, allowing smaller trials to be done [49] .
In summary, cystic fibrosis babies have airflow obstruction when diagnosed on symptoms, and this does not recover even with specialized treatment. This accords with noncystic fibrosis birth cohort studies [50] [51] [52] 53 & ], which have shown that early reductions in spirometry track into adult life.
The LCFC recruited a NBS Cystic Fibrosis birth cohort (2007-2011), again with contemporaneous controls. At 3 months, LCI (measured using respiratory mass spectrometry) was elevated, spirometry was abnormal and there was evidence of hyperinflation in these babies, despite NBS diagnosis and early institution of treatment in a specialist cystic fibrosis centre [54] . At 1 year of age, LCI and functional residual capacity measured with plethysmography remained stable, but FEV0 0.5 (measured instead of first second forced expired volume, FEV 1 at both 3 months and 1 year of age) had improved; the ]. The changes were so mild that they could not be scored reproducibly using the Brody score, even by Allan Brody himself. However, it must be acknowledged that the Brody score is not specifically designed to score very early lung disease. At 2 years of age, spirometry, plethysmography and LCI for the groups were reported in abstract form as being the same as at 1 year old [57] . Reports of longer follow-up of this cohort are awaited. Nutritional status was normal.
AREST-CF studies
This group has only recruited NBS cystic fibrosis babies, but has much longer follow-up than the LCFC group. AREST-CF performs annual lung function (RVRTC, forced oscillation and LCI in infants, and then forced oscillation and spirometry from preschool age), HRCT scanning and bronchoscopy in all cystic fibrosis children, and the lung structure and function results are very different from the LCFC; these differences are yet to be resolved. As with LCFC, early nutritional outcomes are excellent [58] . Unlike LCFC, there are no contemporaneous controls, and there are methodological differences in terms of performance of lung function and HRCT, and scoring of the HRCTs.
The initial AREST-CF report stated that RVRTC was normal in the first 6 months of life, and deteriorated thereafter [59] . However, relatively few babies were studied before 6 months, and a subsequent study was in agreement with the LCFC, namely that early RVRTC was abnormal in cystic fibrosis NBS infants [60] . This latter study reported an association between lung function decline, the isolation of Staphylococcus aureus and P. aeruginosa, and the finding of neutrophil elastase in bronchoalveolar lavage. This study showed that there was a staggering mean decrement of À4 Z-scores at 2 years of age, with an apparent linear decline over the life course. This result is very difficult to understand, given the excellent results in school-age children previously (and subsequently) obtained by this group. There has been no reported dramatic change in treatment protocols. Hence, either this new cohort of cystic fibrosis patients has a very different disease phenotype (for which there is no evidence), or more likely, there was a technical issue with the measurements. An international reference range was used to create Z-scores rather than having contemporaneous controls, and this may have contributed to the disturbing results. The group next reported spirometry at school age which is in accord with the expected good outcomes and not consistent with predictions implicit in the RVRTC data [61 && ].
Fifty-six children were tested at school age (mean age 6.4 AE 1.67 years). Interestingly, nutrition was now reduced compared with normal controls (having previously been normal), albeit the group Z-scores for height, weight and BMI overlapped zero (height À0.39 AE 1.04 vs. 0.45 AE 0.97, P ¼ 0.001; weight À0.21 AE 0.95 vs. 0.66 AE 0.66, P < 0.001; BMI 0.05 AE 0.89 vs. 0.55 AE 0.77, P < 0.01). Lung function was also reduced compared with normal, but only to a modest degree [FEV 0.75 8.3%, 95% confidence interval (CI) À6.6 to À15.9, P ¼ 0.04], and FEV 0.75 /forced vital capacity ratio was reduced by 7.7% (À2.7 to À12.4; P < 0.01); there was no difference in FVC. These lung function data are consistent with Australian registry data for children of this age, and, while no formal comparison has been undertaken with UK registry data, Australian and UK lung function outcomes appear to be similar in early school-aged children. The group had previously defined P. aeruginosa, S. aureus, Haemophilus influenza, Streptococcus pneumonia and Aspergillus species as being proinflammatory in the lower airway [62] . Infection in the first 2 years of life by any of these microorganisms, or the detection of neutrophil elastase on bronchoalveolar lavage, was associated with worse school-age lung spirometry; detection of non-inflammatory pathogens had no effect. Hence, this important study suggests that their previous RVRTC data should be treated cautiously.
The AREST-CF group has also extensively studied lung structural disease using annual HRCTs [63] [64] [65] [66] [67] . Data interpretation is critical; what is reported as structural change may in fact not relate to airway wall disease at all, or may be reversible. Bronchiectasis is traditionally considered to be irreversible, dating from the days when bronchography, a really unpleasant test, was only done on those with really severe disease. With the advent of HRCT, a radiological equivalent of bronchiectasis has been promulgated when the diameter of the bronchus is greater than that of the accompanying artery [67] . Thus, what is being reported is bronchial dilatation rather than a 'pathological' diagnosis of irreversible structural damage that is bronchiectasis. Studies in children without cystic fibrosis have shown that computed tomography (CT) changes may reverse with time and treatment [68, 69] . Air trapping may be evanescent and purely represent distal mucus plugging, and even airway wall thickening may be the result of airway oedema, and both reverse with time. In a preliminary AREST-CF study, airway dilatation and air trapping were not present on repeat HRCT in around 25 and 20% of second scans, respectively [65] . Furthermore, technical aspects such as lung volume during scanning affect the results [66] , and scan techniques should be carefully standardized. Thus, interpretation of subtle HRCT findings should be cautious. Furthermore, reproducibility data, both between scorers, and between occasions in the same scorer, are essential; these are not always clearly reported in some manuscripts.
The major AREST-CF study reported serial HRCTs to 3 years of age, a total of four occasions for HRCT [66] . They confirmed their previous study [64] that in some children, the changes were evanescent, with, for example, 12.5% 'resolving' from 3 to 12 months, and 11.1% resolved by 3 years of age. In the first scans, at 3 months of age, what they term bronchiectasis, but which is more properly described as airway dilatation (as described above) and gas trapping, was common (29 and 68%, respectively). By 3 years of age, gas trapping was of similar prevalence, but the point prevalence of bronchiectasis had risen to 62%, with 84% of babies having had airway dilatation at some point. The major risk factors for bronchiectasis included presentation with meconium ileus, chronic respiratory symptoms reported by parents at the time of HRCT (no patient was scanned during a pulmonary exacerbation), free neutrophil elastase in bronchoalveolar lavage and gas trapping. Importantly, neutrophil elastase in the 3-month bronchoalveolar lavage was associated with persistent airway dilatation (present on >2 sequential scans), with odds of seven times and four times at 12 and 36 months, respectively. AREST-CF has done a great service by highlighting the very early presence of neutrophil elastase in the airway as a marker for adverse long-term respiratory outcomes in terms of both structure and function. Worryingly, the implication is that diagnosis by current NBS screening protocols, which lead to diagnosis at about 4 weeks, may be too late to prevent the initiation of airway damage, and perhaps in the future, genetic screening by whole genome sequencing on cord blood will give better results. This interpretation remains to be proven by longer-term studies.
The AREST-CF group have a limited amount of data correlating LCI with HRCT findings [63] . Fortynine infants had matched HRCT, bronchoscopy and multiple breath washout using SF 6 . They calculated LCI and moment ratios (which are not commonly reported in these studies); there were weak correlations between all these indices and gas trapping, but only the second moment ratio showed a weak correlation with airway dilatation; there was none with either the first moment ratio or LCI. They concluded that, unlike the findings in more advanced cystic fibrosis lung disease [40, 41] , LCI could not be used to reduce the number of HRCT being performed in early life.
WHAT ARE THE IMPLICATIONS OF THESE NEWBORN SCREENING CYSTIC FIBROSIS COHORT STUDIES?
At the start of this review, the compelling importance of understanding the natural history of NBS cystic fibrosis lung disease in order to design randomized controlled trials and also to determine the optimal timing of starting novel molecular therapies was put forward. Can infant and preschool pulmonary function tests assist us at this point? Although the AREST-CF data in this age group would allow RVRTC to be used as a trial end-point, their school-age data suggest that the earlier lung function does not present a true picture. In any event, it is likely that LCI will be a more sensitive end-point than RVRTC; however, both the LCFC and AREST-CF data suggest that LCI is unlikely to be a useful end-point at least up to age 2 years. In terms of HRCT, the LCFC data suggest that up to age 1 year, HRCT will not be useful; the AREST-CF data suggest that, although some changes are evanescent, HRCT could be used as a trial end-point. This could be resolved by having an automated scoring system that is sensitive enough to be used and practical for us, because the traditional approach of taking digital data, converting it into a greyscale and then making a qualitative report, makes no sense. The Perth-Rotterdam Annotated Grid Morphometric Analysis score [70 && ], in which a grid is used to aid scoring, is an advance, but surely purely mathematical analysis must be the way forward in the 21st Century [71] .
Should innovative molecular therapies be deployed at diagnosis? Given the LCFC data, it would seem that they could be delayed by at least 2 years, although such a conclusion must be tentative pending more prolonged follow-up; and this would certainly not be the conclusion of the AREST-CF studies. If they were to be used, studies over several years are likely to be needed to show benefit.
Another question is, what tests should be moved from the research arena to the routine clinic? Given the Australasian bronchoscopy study [72] , it is difficult to justify routine annual bronchoscopy, nor has there been a similar outcome study showing that annual or biannual HRCT improves clinical results. Many are sceptical that HRCT, in a population with a known increased risk of at least some epithelial cancers [73] , is justifiable. LCI is a safe technique, and provided commercial equipment of adequate specification can be made, especially for young infants, it should be introduced into routine clinical practice. A more practical assessment of the presence of neutrophil-dominated pulmonary inflammation with consequent oxidative stress and tissue destruction that can be made on each occasion a child is seen will be required. Such 'point-of-care' biomarkers would be very valuable, but will not come from bronchoscopy and HRCT! What is not controversial is that cystic fibrosis NBS has, however, enabled us to do better than was possible with children diagnosed when they became symptomatic. The question is how to build on that success by moving to evidence-based treatment protocols, including the timing of commencing novel therapies.
CONCLUSION
Cystic fibrosis NBS has led to early diagnosis and institution of treatment at a much earlier stage, with definite benefits to patients compared with previous, late-diagnosed groups. Despite early diagnosis, lung function is impaired at 3 months of age. There is a pressing need for evidence-based treatments after NBS diagnosis, for which knowledge of the natural history of the disease and suitable clinical trial end-points are required. Although more data are required definitively to settle the question, it is likely that in the first 2 years of life, HRCT and lung function will not be suitable clinical trial endpoints. We need biomarkers to predict which infants will go on to have a worse prognosis, and who thus may be suitable candidates for innovative, designer molecule-based therapies.
